Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 5.17
NVDQ's Cash-to-Debt is ranked higher than
57% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NVDQ: 5.17 )
Ranked among companies with meaningful Cash-to-Debt only.
NVDQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: No Debt Max: No Debt
Current: 5.17
Equity-to-Asset 0.71
NVDQ's Equity-to-Asset is ranked higher than
71% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NVDQ: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
NVDQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.81 Max: 0.97
Current: 0.71
-0.16
0.97
Debt-to-Equity 0.11
NVDQ's Debt-to-Equity is ranked higher than
75% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.31 vs. NVDQ: 0.11 )
Ranked among companies with meaningful Debt-to-Equity only.
NVDQ' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.95  Med: 0.19 Max: 6.75
Current: 0.11
-4.95
6.75
Piotroski F-Score: 2
Altman Z-Score: 6.87
Beneish M-Score: -3.64
WACC vs ROIC
-4.94%
-114.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -71.76
NVDQ's Operating Margin % is ranked lower than
70% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. NVDQ: -71.76 )
Ranked among companies with meaningful Operating Margin % only.
NVDQ' s Operating Margin % Range Over the Past 10 Years
Min: -175.15  Med: -62.21 Max: -13.33
Current: -71.76
-175.15
-13.33
Net Margin % -66.69
NVDQ's Net Margin % is ranked lower than
69% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. NVDQ: -66.69 )
Ranked among companies with meaningful Net Margin % only.
NVDQ' s Net Margin % Range Over the Past 10 Years
Min: -182.24  Med: -66.24 Max: -48.31
Current: -66.69
-182.24
-48.31
ROE % -49.42
NVDQ's ROE % is ranked lower than
70% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. NVDQ: -49.42 )
Ranked among companies with meaningful ROE % only.
NVDQ' s ROE % Range Over the Past 10 Years
Min: -522.79  Med: -54.08 Max: -15.03
Current: -49.42
-522.79
-15.03
ROA % -39.92
NVDQ's ROA % is ranked lower than
69% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. NVDQ: -39.92 )
Ranked among companies with meaningful ROA % only.
NVDQ' s ROA % Range Over the Past 10 Years
Min: -95.21  Med: -39.77 Max: -12.4
Current: -39.92
-95.21
-12.4
ROC (Joel Greenblatt) % -147.95
NVDQ's ROC (Joel Greenblatt) % is ranked lower than
66% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NVDQ: -147.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVDQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -852.05  Med: -198.62 Max: -100.51
Current: -147.95
-852.05
-100.51
3-Year Revenue Growth Rate 32.40
NVDQ's 3-Year Revenue Growth Rate is ranked higher than
90% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. NVDQ: 32.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVDQ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.3  Med: 28.85 Max: 143.7
Current: 32.4
-7.3
143.7
3-Year EBITDA Growth Rate 35.10
NVDQ's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NVDQ: 35.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVDQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.2  Med: 5.95 Max: 68.5
Current: 35.1
-31.2
68.5
3-Year EPS without NRI Growth Rate 35.40
NVDQ's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NVDQ: 35.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVDQ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.9  Med: 10.05 Max: 63
Current: 35.4
-26.9
63
GuruFocus has detected 4 Warning Signs with Novadaq Technologies Inc $NVDQ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVDQ's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NVDQ Guru Trades in Q3 2016

Steven Cohen 597,700 sh (+500.10%)
Ron Baron 71,000 sh (+57.78%)
PRIMECAP Management 5,686,349 sh (+4.90%)
Chuck Royce 183,400 sh (-5.42%)
» More
Q4 2016

NVDQ Guru Trades in Q4 2016

Ron Baron 185,600 sh (+161.41%)
Chuck Royce 183,400 sh (unchged)
John Paulson 500,000 sh (unchged)
PRIMECAP Management 5,643,449 sh (-0.75%)
Steven Cohen 194,455 sh (-67.47%)
» More
Q1 2017

NVDQ Guru Trades in Q1 2017

Chuck Royce 603,400 sh (+229.01%)
PRIMECAP Management 5,655,849 sh (+0.22%)
Ron Baron 185,700 sh (+0.05%)
John Paulson 500,000 sh (unchged)
Steven Cohen Sold Out
» More
Q2 2017

NVDQ Guru Trades in Q2 2017

Mario Gabelli 12,380 sh (New)
PRIMECAP Management 5,728,149 sh (+1.28%)
Chuck Royce Sold Out
Ron Baron Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVDQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 New Buy$6 - $11.82 $ 11.7550%12,380
Ron Baron 2017-06-30 Sold Out 0.01%$6 - $11.82 $ 11.7550%0
Ron Baron 2017-03-31 Add 0.05%$6.37 - $8.21 $ 11.7566%185,700
Ron Baron 2016-12-31 Add 161.41%0.01%$7.09 - $11.68 $ 11.7530%185,600
Ron Baron 2016-09-30 Add 57.78%$8.8 - $12.58 $ 11.758%71,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334510    SIC: 8683
Compare:TSX:EDT, TSX:PMN, TSXV:PRN, TSXV:LXG, TSXV:SVA, TSXV:CVM, TSXV:LMD, XCNQ:CHX, TSXV:SQD, TSXV:DXD, TSXV:VPT, TSXV:MDX, TSX:GEN, XCNQ:BUX, XCNQ:BTH, TSXV:IDL, XCNQ:IME, OTCPK:ETAH, TSXV:LMT, TSXV:MBI » details
Traded in other countries:NDQ.Canada, NQT.Germany,
Headquarter Location:Canada
Novadaq Technologies Inc develops & commercializes medical imaging & therapeutic devices for use in the operating room. Its proprietary imaging platform can be used to visualize blood vessels, nerves & the lymphatic system during surgical procedures.

Novadaq Technologies Inc was incorporated under the Canada Business Corporations Act on April 14, 2000. The Company develops and commercializes medical imaging and therapeutic devices for use in the operating room. It's imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company's business activities are conducted through one segment, which consists of medical devices. Its product includes, SPY Elite, PINPOINT Endoscopic Fluorescence Imaging, FIREFLY System for Robotic Surgery, LUNA Fluorescence Angiography and CO2 HEART LASER System. The SPY Imaging System provides clinically relevant information that empowers surgeons to make informed critical decisions in the operating room. PINPOINT Endoscopic Fluorescence Imaging System combines all of the fluorescence imaging capabilities of SPY Imaging with the HD visible light imaging capabilities of a traditional endoscopic imaging system. FIREFLY system enables surgeons performing robotic surgery to benefit from fluorescence imaging, with initial use in applications ranging from urology to gynecology. LUNA fluorescence angiography enables clinicians to visually assess tissue perfusion in diabetic foot ulcers and non-healing wounds. The CO2 HEART LASER System consists of: the CO2 HEART LASER mobile console and the CO2 HEART LASER disposable hand pieces. The Company's intellectual property consists of 49 patent families representing 128 granted or allowed patents and 90 pending applications in various stages of review and prosecution.

Guru Investment Theses on Novadaq Technologies Inc

Baron Funds Comments on Novadaq Technologies - Jan 20, 2017

Novadaq Technologies Inc. (NASDAQ:NVDQ) is a medical imaging company. Its tools, which show blood flow (perfusion), have been clinically proven to dramatically improve outcomes in many types of surgeries, including colon resection (where a segment of colon is removed and the ends are re-attached), breast reconstruction (typically in cancer surgeries), and many other general surgeries. Significant clinical trials are underway with leading medical institutions that will assess the ability of Novadaq devices in guiding complex lymph node surgeries related to the spread of cancer. The company also sells human-based tissue replacement (complementary to breast reconstruction, and potentially useful for diabetic foot ulcer treatment). Shares fell in the fourth quarter due to, what in our opinion was, a misunderstanding of the halting of a clinical trial in colon resection. The company halted the trial (which was to be a larger version of a prior successful trial in the space) because its devices have been proven to be so good that the company couldn’t find doctors willing to forego its use on surgeries needed to create a control group cohort. Another issue holding back the shares is a change of business plan to sell capital equipment to customers over three-to-four years versus an upfront payment, which defers revenue and cash flow. Thus, despite recurring revenues growing at 40-50% rates (half the business), equipment sales growth has slowed to single digits. This has caused overall revenue growth to slow to 25% from about 30%-40% growth. We are assessing the situation, but believe the current multiple reflects the change in business dynamics. Also, because of the model change, more of the company’s revenues will be recurring, making Novadaq more attractive to potential acquirers, particularly at its current valuation.





From Baron Discovery Fund's fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Novadaq Technologies Inc

NOVADAQ Announces Filing With the United States Securities and Exchange Commission to Terminate the Registration of Its Common Shares
NOVADAQ Announces Completion of Plan of Arrangement
NOVADAQ Receives Court Approval for Arrangement With Stryker
Novadaq Announces Voting Results of Special Meeting of Shareholders
Leading Advisory Firms ISS and Glass Lewis Support Plan of Arrangement Between NOVADAQ Technologies Inc. and Stryker Corporation
NOVADAQ Mails Information Circular for Special Meeting of Shareholders
NOVADAQ Enters Into Agreement to be Acquired by Stryker Corporation
NOVADAQ to Present at the Upcoming JMP Securities 2017 Life Sciences Conference
NOVADAQ to Report First Quarter 2017 Financial results on May 3, 2017
NOVADAQ to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017

TORONTO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- NOVADAQ Technologies Inc (NASDAQ:NVDQ) (TSX:NDQ), the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it will release financial results for the fourth quarter and full year 2016 after the close of trading on Tuesday, February 28, 2017. The Company’s management team will host a corresponding conference call beginning at 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing 877-407-8031 (within Canada and the U.S.) or 201-689-8031 (outside Canada and the U.S.).  A live and archived webcast of the event will be available on the “Investor Relations” section of the Company’s website at: www.novadaq.com. A replay of the call will be available for 48 hours by calling 877-481-4010 (within Canada and the U.S.) or 919-882-2331 (outside Canada and the U.S.), using Conference ID: 10229. About NOVADAQ Technologies Inc. 
NOVADAQ’s global mission is to enable physicians with point-of-care imaging solutions that provide real-time clinically significant and actionable information to improve care quality and lower healthcare costs. Using NOVADAQ’s SPY fluorescence imaging technology, physicians can personalize therapy and achieve optimal results through the precise visualization of blood flow in vessels, micro-vessels, tissue perfusion and critical anatomical structures during the course of treatment. SPY technology enables the delivery of personalized therapies and the achievement of the optimal results for each individual patient. More than 230 peer-reviewed publications demonstrate that the use of SPY technology will reduce post-procedure complication rates and the cost of care for a broad variety of surgical treatments for cancer, cardiovascular diseases and other conditions, helping to ensure that patients benefit from the very best possible treatment and outcome. SPY Imaging Systems are U.S. Food and Drug Administration 510(k) cleared, Health Canada licensed, CE Marked and registered worldwide for use in multiple surgical specialties and medical applications. The endoscopic version of SPY technology, known as PINPOINT, combines the fluorescence imaging capabilities of SPY with the high definition visible light visualization to establish a new standard in the quality and performance of minimally invasive surgery. NOVADAQ’s LUNA System is used to visualize blood flow and tissue perfusion while treating patients with atherosclerotic cardiovascular disease that impairs blood flow to the extremities and increases the risk for the development of complications such as acute and chronic non-healing wounds and limb loss. NOVADAQ is the exclusive worldwide distributor of LifeNet Health’s DermACELL acellular tissue products for wound and breast reconstruction surgery NOVADAQ, SPY, PINPOINT, LUNA and the illumination square design are registered trademarks of NOVADAQ Technologies, Inc. DermACELL is a registered trademark of LifeNet Health, Inc.
For more information, please contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 6.96
NVDQ's PB Ratio is ranked lower than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. NVDQ: 6.96 )
Ranked among companies with meaningful PB Ratio only.
NVDQ' s PB Ratio Range Over the Past 10 Years
Min: 0.91  Med: 5.24 Max: 274
Current: 6.96
0.91
274
PS Ratio 7.39
NVDQ's PS Ratio is ranked lower than
71% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. NVDQ: 7.39 )
Ranked among companies with meaningful PS Ratio only.
NVDQ' s PS Ratio Range Over the Past 10 Years
Min: 1.63  Med: 10.87 Max: 79.23
Current: 7.39
1.63
79.23
EV-to-EBIT -10.62
NVDQ's EV-to-EBIT is ranked lower than
99.99% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NVDQ: -10.62 )
Ranked among companies with meaningful EV-to-EBIT only.
NVDQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -81.5  Med: -13.05 Max: -0.7
Current: -10.62
-81.5
-0.7
EV-to-EBITDA -12.87
NVDQ's EV-to-EBITDA is ranked lower than
99.99% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. NVDQ: -12.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVDQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -175.3  Med: -15.95 Max: -0.8
Current: -12.87
-175.3
-0.8
EV-to-Revenue 6.98
NVDQ's EV-to-Revenue is ranked lower than
69% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. NVDQ: 6.98 )
Ranked among companies with meaningful EV-to-Revenue only.
NVDQ' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 10.2 Max: 71.1
Current: 6.98
1.1
71.1
Current Ratio 3.49
NVDQ's Current Ratio is ranked higher than
70% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. NVDQ: 3.49 )
Ranked among companies with meaningful Current Ratio only.
NVDQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 6.74 Max: 26.52
Current: 3.49
1
26.52
Quick Ratio 3.30
NVDQ's Quick Ratio is ranked higher than
72% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. NVDQ: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
NVDQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 6.15 Max: 26.46
Current: 3.3
0.85
26.46
Days Inventory 76.17
NVDQ's Days Inventory is ranked lower than
59% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. NVDQ: 76.17 )
Ranked among companies with meaningful Days Inventory only.
NVDQ' s Days Inventory Range Over the Past 10 Years
Min: 53.18  Med: 80.4 Max: 159.8
Current: 76.17
53.18
159.8
Days Sales Outstanding 119.92
NVDQ's Days Sales Outstanding is ranked lower than
83% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. NVDQ: 119.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVDQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.76  Med: 92.13 Max: 168.34
Current: 119.92
37.76
168.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
NVDQ's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. NVDQ: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVDQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.3  Med: -11.35 Max: -1.5
Current: -1.5
-25.3
-1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 48.96
NVDQ's Price-to-Net-Cash is ranked lower than
78% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.16 vs. NVDQ: 48.96 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NVDQ' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.37  Med: 9.16 Max: 63.75
Current: 48.96
5.37
63.75
Price-to-Net-Current-Asset-Value 12.24
NVDQ's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.24 vs. NVDQ: 12.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVDQ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.31  Med: 7.08 Max: 88.33
Current: 12.24
4.31
88.33
Price-to-Tangible-Book 8.51
NVDQ's Price-to-Tangible-Book is ranked lower than
68% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.17 vs. NVDQ: 8.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVDQ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.62  Med: 6.37 Max: 650
Current: 8.51
2.62
650
Price-to-Median-PS-Value 0.68
NVDQ's Price-to-Median-PS-Value is ranked higher than
74% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. NVDQ: 0.68 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVDQ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.06 Max: 27.14
Current: 0.68
0.19
27.14
Earnings Yield (Greenblatt) % -9.42
NVDQ's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. NVDQ: -9.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVDQ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -139.2  Med: -7.7 Max: -1.2
Current: -9.42
-139.2
-1.2

More Statistics

Revenue (TTM) (Mil) $83.87
EPS (TTM) $ -0.97
Beta1.32
Short Percentage of Float0.00%
52-Week Range $5.84 - 12.74
Shares Outstanding (Mil)57.82

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 100 129 178
EPS ($) -0.82 -0.51 0.61
EPS without NRI ($) -0.82 -0.51 0.61
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NVDQ

Headlines

Articles On GuruFocus.com
NOVADAQ Announces Filing With the United States Securities and Exchange Commission to Terminate the Sep 11 2017 
NOVADAQ Announces Completion of Plan of Arrangement Sep 01 2017 
NOVADAQ Receives Court Approval for Arrangement With Stryker Aug 09 2017 
Novadaq Announces Voting Results of Special Meeting of Shareholders Aug 04 2017 
Leading Advisory Firms ISS and Glass Lewis Support Plan of Arrangement Between NOVADAQ Technologies Jul 24 2017 
NOVADAQ Mails Information Circular for Special Meeting of Shareholders Jul 12 2017 
NOVADAQ Enters Into Agreement to be Acquired by Stryker Corporation Jun 19 2017 
NOVADAQ to Present at the Upcoming JMP Securities 2017 Life Sciences Conference Jun 07 2017 
NOVADAQ to Report First Quarter 2017 Financial results on May 3, 2017 Apr 19 2017 
NOVADAQ to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017 Feb 15 2017 

More From Other Websites
NOVADAQ Announces Filing With the United States Securities and Exchange Commission to Terminate the... Sep 11 2017
Novadaq Technologies, Inc. – Value Analysis (NASDAQ:NVDQ) : September 2, 2017 Sep 01 2017
NOVADAQ Announces Completion of Plan of Arrangement Sep 01 2017
Novadaq Technologies, Inc. breached its 50 day moving average in a Bullish Manner : NVDQ-US : August... Aug 29 2017
Novadaq reports 2Q loss Aug 11 2017
NOVADAQ Receives Court Approval for Arrangement With Stryker Aug 09 2017
Novadaq Announces Voting Results of Special Meeting of Shareholders Aug 04 2017
Why Stryker Updated 2017 Guidance during 2Q17 Earnings Release Jul 31 2017
Leading Advisory Firms ISS and Glass Lewis Support Plan of Arrangement Between NOVADAQ Technologies... Jul 24 2017
Stryker Acquires Novadaq, Enhances Its Endoscopic Offerings Jul 20 2017
NOVADAQ Mails Information Circular for Special Meeting of Shareholders Jul 12 2017
Novadaq Technologies, Inc. – Value Analysis (NASDAQ:NVDQ) : June 22, 2017 Jun 22 2017
Company News for June 20, 2017 Jun 20 2017
Novadaq Technologies Inc. (NVDQ) Acquisition Could Spark a Bidding War Jun 20 2017
Why Novadaq Technologies Inc. Skyrocketed Yesterday Jun 20 2017
Novadaq Technologies, Inc. breached its 50 day moving average in a Bullish Manner : NVDQ-US : June... Jun 20 2017
Wall Street's M&A Chatter From June 19: CareerBuilder, EQT-Rice Energy, Novadaq-Stryker Jun 20 2017
Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal Jun 19 2017
Why Valeant Pharmaceuticals, Rite Aid, and Novadaq Technologies Jumped Today Jun 19 2017
Novadaq Technologies (NVDQ) Stock Soars 95% on Stryker Acquisition Deal Jun 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}